nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SRC—pancreatic cancer	0.216	1	CbGaD
Dasatinib—FYN—Sunitinib—pancreatic cancer	0.0284	0.056	CbGbCtD
Dasatinib—JAK2—Sunitinib—pancreatic cancer	0.0284	0.056	CbGbCtD
Dasatinib—FMO3—Tamoxifen—pancreatic cancer	0.0265	0.0523	CbGbCtD
Dasatinib—ABL2—Erlotinib—pancreatic cancer	0.0248	0.0489	CbGbCtD
Dasatinib—MAP4K5—Sunitinib—pancreatic cancer	0.0238	0.0469	CbGbCtD
Dasatinib—MAP3K3—Sunitinib—pancreatic cancer	0.0238	0.0469	CbGbCtD
Dasatinib—YES1—Sunitinib—pancreatic cancer	0.0238	0.0469	CbGbCtD
Dasatinib—MAP2K5—Erlotinib—pancreatic cancer	0.0225	0.0445	CbGbCtD
Dasatinib—MAP3K19—Erlotinib—pancreatic cancer	0.0207	0.0409	CbGbCtD
Dasatinib—MAP3K2—Sunitinib—pancreatic cancer	0.0205	0.0405	CbGbCtD
Dasatinib—FGR—Sunitinib—pancreatic cancer	0.0205	0.0405	CbGbCtD
Dasatinib—EPHB6—Sunitinib—pancreatic cancer	0.0181	0.0358	CbGbCtD
Dasatinib—BLK—Sunitinib—pancreatic cancer	0.0181	0.0358	CbGbCtD
Dasatinib—ABL1—Erlotinib—pancreatic cancer	0.0179	0.0353	CbGbCtD
Dasatinib—KIT—Sunitinib—pancreatic cancer	0.0163	0.0322	CbGbCtD
Dasatinib—CSF1R—Sunitinib—pancreatic cancer	0.0163	0.0322	CbGbCtD
Dasatinib—PDGFRA—Sunitinib—pancreatic cancer	0.0163	0.0322	CbGbCtD
Dasatinib—MAP2K5—Sunitinib—pancreatic cancer	0.0148	0.0293	CbGbCtD
Dasatinib—PDGFRB—Sunitinib—pancreatic cancer	0.0148	0.0293	CbGbCtD
Dasatinib—MAP3K19—Sunitinib—pancreatic cancer	0.0136	0.0269	CbGbCtD
Dasatinib—CYP1B1—Tamoxifen—pancreatic cancer	0.0101	0.02	CbGbCtD
Dasatinib—CYP1B1—Erlotinib—pancreatic cancer	0.0086	0.017	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—pancreatic cancer	0.00569	0.0112	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—pancreatic cancer	0.00558	0.011	CbGbCtD
Dasatinib—ABCG2—Tamoxifen—pancreatic cancer	0.00481	0.00949	CbGbCtD
Dasatinib—CYP1A1—Tamoxifen—pancreatic cancer	0.00444	0.00876	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—pancreatic cancer	0.00424	0.00837	CbGbCtD
Dasatinib—ABCG2—Erlotinib—pancreatic cancer	0.00409	0.00807	CbGbCtD
Dasatinib—CYP1A1—Erlotinib—pancreatic cancer	0.00377	0.00745	CbGbCtD
Dasatinib—ABCG2—Irinotecan—pancreatic cancer	0.00369	0.00729	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—pancreatic cancer	0.00354	0.00699	CbGbCtD
Dasatinib—ABCG2—Docetaxel—pancreatic cancer	0.00271	0.00534	CbGbCtD
Dasatinib—ABCG2—Sunitinib—pancreatic cancer	0.00269	0.00532	CbGbCtD
Dasatinib—CYP3A5—Tamoxifen—pancreatic cancer	0.00266	0.00526	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—pancreatic cancer	0.00249	0.00492	CbGbCtD
Dasatinib—CYP3A5—Erlotinib—pancreatic cancer	0.00226	0.00447	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—pancreatic cancer	0.00205	0.00404	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—pancreatic cancer	0.00202	0.00398	CbGbCtD
Dasatinib—CYP1A2—Tamoxifen—pancreatic cancer	0.00198	0.00391	CbGbCtD
Dasatinib—SRMS—gall bladder—pancreatic cancer	0.00193	0.0616	CbGeAlD
Dasatinib—ABCB1—Tamoxifen—pancreatic cancer	0.00173	0.00342	CbGbCtD
Dasatinib—CYP1A2—Erlotinib—pancreatic cancer	0.00169	0.00333	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—pancreatic cancer	0.0015	0.00296	CbGbCtD
Dasatinib—ABCB1—Gemcitabine—pancreatic cancer	0.00149	0.00295	CbGbCtD
Dasatinib—CYP3A5—Sunitinib—pancreatic cancer	0.00149	0.00294	CbGbCtD
Dasatinib—ABCB1—Erlotinib—pancreatic cancer	0.00147	0.00291	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—pancreatic cancer	0.00146	0.00288	CbGbCtD
Dasatinib—ABCB1—Irinotecan—pancreatic cancer	0.00133	0.00263	CbGbCtD
Dasatinib—STAT5B—islet of Langerhans—pancreatic cancer	0.00117	0.0374	CbGeAlD
Dasatinib—CYP3A4—Tamoxifen—pancreatic cancer	0.00104	0.00205	CbGbCtD
Dasatinib—ABCB1—Docetaxel—pancreatic cancer	0.000975	0.00193	CbGbCtD
Dasatinib—ABCB1—Sunitinib—pancreatic cancer	0.000971	0.00192	CbGbCtD
Dasatinib—CYP3A4—Erlotinib—pancreatic cancer	0.000883	0.00174	CbGbCtD
Dasatinib—TESK1—islet of Langerhans—pancreatic cancer	0.000868	0.0276	CbGeAlD
Dasatinib—STAT5B—pancreas—pancreatic cancer	0.000826	0.0263	CbGeAlD
Dasatinib—PDGFRA—gall bladder—pancreatic cancer	0.000825	0.0263	CbGeAlD
Dasatinib—STK35—islet of Langerhans—pancreatic cancer	0.0008	0.0255	CbGeAlD
Dasatinib—CYP3A4—Irinotecan—pancreatic cancer	0.000798	0.00157	CbGbCtD
Dasatinib—CSK—islet of Langerhans—pancreatic cancer	0.000795	0.0253	CbGeAlD
Dasatinib—EPHB2—digestive system—pancreatic cancer	0.000778	0.0248	CbGeAlD
Dasatinib—SRMS—digestive system—pancreatic cancer	0.000761	0.0242	CbGeAlD
Dasatinib—PTK6—digestive system—pancreatic cancer	0.000746	0.0238	CbGeAlD
Dasatinib—RIPK2—islet of Langerhans—pancreatic cancer	0.000738	0.0235	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—pancreatic cancer	0.000727	0.00144	CbGbCtD
Dasatinib—SIK1—islet of Langerhans—pancreatic cancer	0.000721	0.023	CbGeAlD
Dasatinib—STAT5B—digestive system—pancreatic cancer	0.000705	0.0225	CbGeAlD
Dasatinib—KIT—gall bladder—pancreatic cancer	0.000659	0.021	CbGeAlD
Dasatinib—PDGFRB—gall bladder—pancreatic cancer	0.000644	0.0205	CbGeAlD
Dasatinib—EPHB4—islet of Langerhans—pancreatic cancer	0.000623	0.0199	CbGeAlD
Dasatinib—EPHA2—islet of Langerhans—pancreatic cancer	0.000612	0.0195	CbGeAlD
Dasatinib—MAP4K5—islet of Langerhans—pancreatic cancer	0.000597	0.019	CbGeAlD
Dasatinib—ZAK—digestive system—pancreatic cancer	0.000589	0.0188	CbGeAlD
Dasatinib—CYP3A4—Docetaxel—pancreatic cancer	0.000584	0.00115	CbGbCtD
Dasatinib—CYP3A4—Sunitinib—pancreatic cancer	0.000582	0.00115	CbGbCtD
Dasatinib—EPHA5—digestive system—pancreatic cancer	0.000577	0.0184	CbGeAlD
Dasatinib—EPHB6—islet of Langerhans—pancreatic cancer	0.00057	0.0182	CbGeAlD
Dasatinib—STK35—pancreas—pancreatic cancer	0.000563	0.0179	CbGeAlD
Dasatinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.00056	0.274	CbGdCrCtD
Dasatinib—CSK—pancreas—pancreatic cancer	0.000559	0.0178	CbGeAlD
Dasatinib—YES1—islet of Langerhans—pancreatic cancer	0.000551	0.0176	CbGeAlD
Dasatinib—SRC—islet of Langerhans—pancreatic cancer	0.00053	0.0169	CbGeAlD
Dasatinib—EPHB3—digestive system—pancreatic cancer	0.000513	0.0163	CbGeAlD
Dasatinib—SIK1—pancreas—pancreatic cancer	0.000507	0.0161	CbGeAlD
Dasatinib—ERBB3—pancreas—pancreatic cancer	0.000496	0.0158	CbGeAlD
Dasatinib—CSK—digestive system—pancreatic cancer	0.000477	0.0152	CbGeAlD
Dasatinib—HCK—digestive system—pancreatic cancer	0.000471	0.015	CbGeAlD
Dasatinib—RIPK2—digestive system—pancreatic cancer	0.000443	0.0141	CbGeAlD
Dasatinib—EPHB4—pancreas—pancreatic cancer	0.000438	0.014	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000436	0.00086	CbGbCtD
Dasatinib—EPHA2—pancreas—pancreatic cancer	0.00043	0.0137	CbGeAlD
Dasatinib—ERBB3—digestive system—pancreatic cancer	0.000424	0.0135	CbGeAlD
Dasatinib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000422	0.0134	CbGeAlD
Dasatinib—MAP4K5—pancreas—pancreatic cancer	0.000419	0.0134	CbGeAlD
Dasatinib—MAPK14—digestive system—pancreatic cancer	0.000395	0.0126	CbGeAlD
Dasatinib—FGR—digestive system—pancreatic cancer	0.000393	0.0125	CbGeAlD
Dasatinib—YES1—pancreas—pancreatic cancer	0.000387	0.0123	CbGeAlD
Dasatinib—ABL1—islet of Langerhans—pancreatic cancer	0.000376	0.012	CbGeAlD
Dasatinib—EPHB4—digestive system—pancreatic cancer	0.000374	0.0119	CbGeAlD
Dasatinib—SRC—pancreas—pancreatic cancer	0.000373	0.0119	CbGeAlD
Dasatinib—JAK2—digestive system—pancreatic cancer	0.000372	0.0118	CbGeAlD
Dasatinib—EPHA2—digestive system—pancreatic cancer	0.000367	0.0117	CbGeAlD
Dasatinib—FYN—digestive system—pancreatic cancer	0.000367	0.0117	CbGeAlD
Dasatinib—YES1—digestive system—pancreatic cancer	0.000331	0.0105	CbGeAlD
Dasatinib—PDGFRA—digestive system—pancreatic cancer	0.000325	0.0103	CbGeAlD
Dasatinib—SRC—digestive system—pancreatic cancer	0.000318	0.0101	CbGeAlD
Dasatinib—KIT—pancreas—pancreatic cancer	0.000304	0.00968	CbGeAlD
Dasatinib—PDGFRB—pancreas—pancreatic cancer	0.000297	0.00945	CbGeAlD
Dasatinib—CSF1R—digestive system—pancreatic cancer	0.000286	0.0091	CbGeAlD
Dasatinib—ABL1—pancreas—pancreatic cancer	0.000264	0.00843	CbGeAlD
Dasatinib—KIT—digestive system—pancreatic cancer	0.000259	0.00827	CbGeAlD
Dasatinib—PDGFRB—digestive system—pancreatic cancer	0.000253	0.00807	CbGeAlD
Dasatinib—ABL1—digestive system—pancreatic cancer	0.000226	0.0072	CbGeAlD
Dasatinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.00022	0.00702	CbGeAlD
Dasatinib—CYP1B1—digestive system—pancreatic cancer	0.000191	0.00609	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—pancreatic cancer	0.000189	0.0921	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—pancreatic cancer	0.000189	0.0921	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—pancreatic cancer	0.000175	0.0853	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—pancreatic cancer	0.000175	0.0853	CbGdCrCtD
Dasatinib—CYP3A5—pancreas—pancreatic cancer	0.000155	0.00493	CbGeAlD
Dasatinib—CYP1A2—digestive system—pancreatic cancer	0.000137	0.00437	CbGeAlD
Dasatinib—CYP1A1—digestive system—pancreatic cancer	0.000135	0.00431	CbGeAlD
Dasatinib—CYP3A5—digestive system—pancreatic cancer	0.000132	0.00421	CbGeAlD
Dasatinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	0.000132	0.0643	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	0.000132	0.0643	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	0.000132	0.0643	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	0.000122	0.0595	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	0.000122	0.0595	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	0.000122	0.0595	CbGdCrCtD
Dasatinib—ABCB1—islet of Langerhans—pancreatic cancer	0.000117	0.00373	CbGeAlD
Dasatinib—CYP3A4—digestive system—pancreatic cancer	9.92e-05	0.00316	CbGeAlD
Dasatinib—ABCB1—pancreas—pancreatic cancer	8.22e-05	0.00262	CbGeAlD
Dasatinib—ABCB1—digestive system—pancreatic cancer	7.02e-05	0.00224	CbGeAlD
Dasatinib—Cough—Docetaxel—pancreatic cancer	4.02e-05	0.000342	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—pancreatic cancer	4.02e-05	0.000342	CcSEcCtD
Dasatinib—Hypersensitivity—Irinotecan—pancreatic cancer	4e-05	0.000341	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—pancreatic cancer	4e-05	0.00034	CcSEcCtD
Dasatinib—Convulsion—Docetaxel—pancreatic cancer	3.99e-05	0.000339	CcSEcCtD
Dasatinib—Hypertension—Docetaxel—pancreatic cancer	3.98e-05	0.000338	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—pancreatic cancer	3.97e-05	0.000338	CcSEcCtD
Dasatinib—Infestation—Epirubicin—pancreatic cancer	3.97e-05	0.000338	CcSEcCtD
Dasatinib—Chest pain—Docetaxel—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Dasatinib—Arthralgia—Docetaxel—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Dasatinib—Myalgia—Docetaxel—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Dasatinib—Nausea—Sunitinib—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—pancreatic cancer	3.91e-05	0.000332	CcSEcCtD
Dasatinib—Asthenia—Irinotecan—pancreatic cancer	3.9e-05	0.000332	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—pancreatic cancer	3.9e-05	0.000331	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	3.89e-05	0.000331	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—pancreatic cancer	3.87e-05	0.00033	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—pancreatic cancer	3.86e-05	0.000329	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—pancreatic cancer	3.86e-05	0.000328	CcSEcCtD
Dasatinib—Hypersensitivity—Fluorouracil—pancreatic cancer	3.84e-05	0.000326	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	3.83e-05	0.000326	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—pancreatic cancer	3.81e-05	0.000324	CcSEcCtD
Dasatinib—Asthenia—Gemcitabine—pancreatic cancer	3.8e-05	0.000323	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—pancreatic cancer	3.79e-05	0.000322	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—pancreatic cancer	3.79e-05	0.000322	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	3.76e-05	0.00032	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	3.76e-05	0.00032	CcSEcCtD
Dasatinib—Oedema—Docetaxel—pancreatic cancer	3.76e-05	0.00032	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—pancreatic cancer	3.75e-05	0.000319	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—pancreatic cancer	3.75e-05	0.000319	CcSEcCtD
Dasatinib—Pruritus—Gemcitabine—pancreatic cancer	3.75e-05	0.000319	CcSEcCtD
Dasatinib—Infection—Docetaxel—pancreatic cancer	3.73e-05	0.000318	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—pancreatic cancer	3.73e-05	0.000317	CcSEcCtD
Dasatinib—Diarrhoea—Irinotecan—pancreatic cancer	3.72e-05	0.000316	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—pancreatic cancer	3.7e-05	0.000315	CcSEcCtD
Dasatinib—Shock—Docetaxel—pancreatic cancer	3.7e-05	0.000315	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—pancreatic cancer	3.69e-05	0.000314	CcSEcCtD
Dasatinib—Pruritus—Fluorouracil—pancreatic cancer	3.68e-05	0.000313	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—pancreatic cancer	3.68e-05	0.000313	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—pancreatic cancer	3.68e-05	0.000313	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—pancreatic cancer	3.68e-05	0.000313	CcSEcCtD
Dasatinib—Tachycardia—Docetaxel—pancreatic cancer	3.67e-05	0.000312	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—pancreatic cancer	3.65e-05	0.000311	CcSEcCtD
Dasatinib—Diarrhoea—Gemcitabine—pancreatic cancer	3.62e-05	0.000308	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—pancreatic cancer	3.61e-05	0.000308	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	3.6e-05	0.000307	CcSEcCtD
Dasatinib—Dizziness—Irinotecan—pancreatic cancer	3.59e-05	0.000306	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—pancreatic cancer	3.59e-05	0.000305	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—pancreatic cancer	3.58e-05	0.000305	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—pancreatic cancer	3.58e-05	0.000305	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—pancreatic cancer	3.57e-05	0.000304	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—pancreatic cancer	3.57e-05	0.000304	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—pancreatic cancer	3.57e-05	0.000304	CcSEcCtD
Dasatinib—Diarrhoea—Fluorouracil—pancreatic cancer	3.56e-05	0.000303	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—pancreatic cancer	3.52e-05	0.0003	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—pancreatic cancer	3.51e-05	0.000299	CcSEcCtD
Dasatinib—Hypotension—Docetaxel—pancreatic cancer	3.51e-05	0.000299	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—pancreatic cancer	3.51e-05	0.000298	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—pancreatic cancer	3.51e-05	0.000298	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—pancreatic cancer	3.5e-05	0.000298	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	3.48e-05	0.000296	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—pancreatic cancer	3.47e-05	0.000295	CcSEcCtD
Dasatinib—Vomiting—Irinotecan—pancreatic cancer	3.46e-05	0.000294	CcSEcCtD
Dasatinib—Dizziness—Fluorouracil—pancreatic cancer	3.44e-05	0.000293	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—pancreatic cancer	3.44e-05	0.000292	CcSEcCtD
Dasatinib—Rash—Irinotecan—pancreatic cancer	3.43e-05	0.000292	CcSEcCtD
Dasatinib—Dermatitis—Irinotecan—pancreatic cancer	3.42e-05	0.000291	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	3.42e-05	0.000291	CcSEcCtD
Dasatinib—Headache—Irinotecan—pancreatic cancer	3.41e-05	0.00029	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—pancreatic cancer	3.4e-05	0.000289	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—pancreatic cancer	3.37e-05	0.000287	CcSEcCtD
Dasatinib—Vomiting—Gemcitabine—pancreatic cancer	3.37e-05	0.000286	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—pancreatic cancer	3.35e-05	0.000285	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—pancreatic cancer	3.34e-05	0.000284	CcSEcCtD
Dasatinib—Rash—Gemcitabine—pancreatic cancer	3.34e-05	0.000284	CcSEcCtD
Dasatinib—Dermatitis—Gemcitabine—pancreatic cancer	3.34e-05	0.000284	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—pancreatic cancer	3.33e-05	0.000284	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—pancreatic cancer	3.33e-05	0.000283	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—pancreatic cancer	3.32e-05	0.000282	CcSEcCtD
Dasatinib—Headache—Gemcitabine—pancreatic cancer	3.32e-05	0.000282	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—pancreatic cancer	3.31e-05	0.000282	CcSEcCtD
Dasatinib—Flushing—Epirubicin—pancreatic cancer	3.31e-05	0.000282	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—pancreatic cancer	3.31e-05	0.000282	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—pancreatic cancer	3.31e-05	0.000281	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—pancreatic cancer	3.3e-05	0.000281	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—pancreatic cancer	3.3e-05	0.000281	CcSEcCtD
Dasatinib—Rash—Fluorouracil—pancreatic cancer	3.28e-05	0.000279	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—pancreatic cancer	3.28e-05	0.000279	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—pancreatic cancer	3.27e-05	0.000278	CcSEcCtD
Dasatinib—Headache—Fluorouracil—pancreatic cancer	3.26e-05	0.000277	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	3.26e-05	0.000277	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—pancreatic cancer	3.25e-05	0.000277	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	3.24e-05	0.000276	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	3.24e-05	0.000276	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—pancreatic cancer	3.24e-05	0.000276	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—pancreatic cancer	3.24e-05	0.000275	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—pancreatic cancer	3.24e-05	0.000275	CcSEcCtD
Dasatinib—Nausea—Irinotecan—pancreatic cancer	3.23e-05	0.000275	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—pancreatic cancer	3.22e-05	0.000274	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—pancreatic cancer	3.22e-05	0.000274	CcSEcCtD
Dasatinib—Pain—Docetaxel—pancreatic cancer	3.21e-05	0.000273	CcSEcCtD
Dasatinib—Constipation—Docetaxel—pancreatic cancer	3.21e-05	0.000273	CcSEcCtD
Dasatinib—Chills—Epirubicin—pancreatic cancer	3.2e-05	0.000272	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—pancreatic cancer	3.19e-05	0.000271	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—pancreatic cancer	3.18e-05	0.000271	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—pancreatic cancer	3.15e-05	0.000268	CcSEcCtD
Dasatinib—Nausea—Gemcitabine—pancreatic cancer	3.15e-05	0.000268	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—pancreatic cancer	3.13e-05	0.000266	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—pancreatic cancer	3.12e-05	0.000266	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—pancreatic cancer	3.11e-05	0.000264	CcSEcCtD
Dasatinib—Erythema—Epirubicin—pancreatic cancer	3.11e-05	0.000264	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—pancreatic cancer	3.1e-05	0.000263	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—pancreatic cancer	3.09e-05	0.000263	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—pancreatic cancer	3.08e-05	0.000262	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—pancreatic cancer	3.08e-05	0.000262	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	3.07e-05	0.000261	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—pancreatic cancer	3.06e-05	0.000261	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—pancreatic cancer	3.06e-05	0.000261	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—pancreatic cancer	3.04e-05	0.000259	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—pancreatic cancer	2.99e-05	0.000255	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—pancreatic cancer	2.99e-05	0.000254	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—pancreatic cancer	2.98e-05	0.000254	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.97e-05	0.000253	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—pancreatic cancer	2.97e-05	0.000253	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—pancreatic cancer	2.97e-05	0.000253	CcSEcCtD
Dasatinib—Chills—Doxorubicin—pancreatic cancer	2.96e-05	0.000252	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—pancreatic cancer	2.95e-05	0.000251	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—pancreatic cancer	2.93e-05	0.000249	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—pancreatic cancer	2.92e-05	0.000248	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—pancreatic cancer	2.89e-05	0.000246	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—pancreatic cancer	2.88e-05	0.000245	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—pancreatic cancer	2.87e-05	0.000244	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—pancreatic cancer	2.87e-05	0.000244	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—pancreatic cancer	2.87e-05	0.000244	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—pancreatic cancer	2.81e-05	0.000239	CcSEcCtD
Dasatinib—Malaise—Epirubicin—pancreatic cancer	2.8e-05	0.000238	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—pancreatic cancer	2.79e-05	0.000237	CcSEcCtD
Dasatinib—Syncope—Epirubicin—pancreatic cancer	2.78e-05	0.000237	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—pancreatic cancer	2.77e-05	0.000236	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—pancreatic cancer	2.76e-05	0.000235	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—pancreatic cancer	2.74e-05	0.000233	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—pancreatic cancer	2.73e-05	0.000232	CcSEcCtD
Dasatinib—Cough—Epirubicin—pancreatic cancer	2.71e-05	0.000231	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—pancreatic cancer	2.71e-05	0.00023	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—pancreatic cancer	2.7e-05	0.000229	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—pancreatic cancer	2.69e-05	0.000229	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—pancreatic cancer	2.68e-05	0.000228	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—pancreatic cancer	2.67e-05	0.000227	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—pancreatic cancer	2.66e-05	0.000226	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—pancreatic cancer	2.66e-05	0.000226	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—pancreatic cancer	2.63e-05	0.000224	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.63e-05	0.000223	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—pancreatic cancer	2.61e-05	0.000222	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—pancreatic cancer	2.59e-05	0.00022	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—pancreatic cancer	2.58e-05	0.00022	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—pancreatic cancer	2.58e-05	0.000219	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—pancreatic cancer	2.57e-05	0.000219	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—pancreatic cancer	2.56e-05	0.000217	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—pancreatic cancer	2.54e-05	0.000216	CcSEcCtD
Dasatinib—Oedema—Epirubicin—pancreatic cancer	2.53e-05	0.000216	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—pancreatic cancer	2.53e-05	0.000215	CcSEcCtD
Dasatinib—Infection—Epirubicin—pancreatic cancer	2.52e-05	0.000214	CcSEcCtD
Dasatinib—Cough—Doxorubicin—pancreatic cancer	2.51e-05	0.000213	CcSEcCtD
Dasatinib—Shock—Epirubicin—pancreatic cancer	2.49e-05	0.000212	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—pancreatic cancer	2.49e-05	0.000212	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—pancreatic cancer	2.49e-05	0.000211	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—pancreatic cancer	2.48e-05	0.000211	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—pancreatic cancer	2.48e-05	0.000211	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—pancreatic cancer	2.48e-05	0.000211	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—pancreatic cancer	2.47e-05	0.00021	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—pancreatic cancer	2.46e-05	0.000209	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—pancreatic cancer	2.45e-05	0.000208	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—pancreatic cancer	2.45e-05	0.000208	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—pancreatic cancer	2.45e-05	0.000208	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—pancreatic cancer	2.45e-05	0.000208	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—pancreatic cancer	2.44e-05	0.000207	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	2.43e-05	0.000207	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—pancreatic cancer	2.42e-05	0.000206	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—pancreatic cancer	2.42e-05	0.000206	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—pancreatic cancer	2.39e-05	0.000203	CcSEcCtD
Dasatinib—Rash—Docetaxel—pancreatic cancer	2.37e-05	0.000202	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—pancreatic cancer	2.37e-05	0.000201	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—pancreatic cancer	2.37e-05	0.000201	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—pancreatic cancer	2.36e-05	0.000201	CcSEcCtD
Dasatinib—Headache—Docetaxel—pancreatic cancer	2.35e-05	0.0002	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—pancreatic cancer	2.35e-05	0.0002	CcSEcCtD
Dasatinib—Infection—Doxorubicin—pancreatic cancer	2.33e-05	0.000198	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.31e-05	0.000196	CcSEcCtD
Dasatinib—Shock—Doxorubicin—pancreatic cancer	2.31e-05	0.000196	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—pancreatic cancer	2.3e-05	0.000196	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.3e-05	0.000195	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—pancreatic cancer	2.29e-05	0.000195	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—pancreatic cancer	2.29e-05	0.000195	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—pancreatic cancer	2.28e-05	0.000194	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—pancreatic cancer	2.27e-05	0.000193	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—pancreatic cancer	2.26e-05	0.000192	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—pancreatic cancer	2.25e-05	0.000192	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—pancreatic cancer	2.24e-05	0.00019	CcSEcCtD
Dasatinib—Nausea—Docetaxel—pancreatic cancer	2.23e-05	0.00019	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—pancreatic cancer	2.23e-05	0.00019	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—pancreatic cancer	2.2e-05	0.000187	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—pancreatic cancer	2.19e-05	0.000186	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.19e-05	0.000186	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—pancreatic cancer	2.19e-05	0.000186	CcSEcCtD
Dasatinib—Constipation—Epirubicin—pancreatic cancer	2.17e-05	0.000184	CcSEcCtD
Dasatinib—Pain—Epirubicin—pancreatic cancer	2.17e-05	0.000184	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.14e-05	0.000182	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—pancreatic cancer	2.12e-05	0.00018	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—pancreatic cancer	2.09e-05	0.000178	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—pancreatic cancer	2.09e-05	0.000178	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—pancreatic cancer	2.08e-05	0.000177	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.07e-05	0.000176	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—pancreatic cancer	2.06e-05	0.000176	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—pancreatic cancer	2.04e-05	0.000173	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.02e-05	0.000172	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—pancreatic cancer	2.02e-05	0.000172	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—pancreatic cancer	2.01e-05	0.000171	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—pancreatic cancer	2.01e-05	0.000171	CcSEcCtD
Dasatinib—Pain—Doxorubicin—pancreatic cancer	2.01e-05	0.000171	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—pancreatic cancer	2e-05	0.00017	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—pancreatic cancer	2e-05	0.00017	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—pancreatic cancer	1.93e-05	0.000164	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.92e-05	0.000163	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—pancreatic cancer	1.87e-05	0.000159	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—pancreatic cancer	1.86e-05	0.000159	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.85e-05	0.000158	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.85e-05	0.000158	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—pancreatic cancer	1.82e-05	0.000155	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—pancreatic cancer	1.79e-05	0.000153	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—pancreatic cancer	1.73e-05	0.000148	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—pancreatic cancer	1.73e-05	0.000147	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—pancreatic cancer	1.68e-05	0.000143	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—pancreatic cancer	1.68e-05	0.000143	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—pancreatic cancer	1.66e-05	0.000141	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—pancreatic cancer	1.61e-05	0.000137	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.6e-05	0.000137	CcSEcCtD
Dasatinib—Rash—Epirubicin—pancreatic cancer	1.6e-05	0.000136	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—pancreatic cancer	1.6e-05	0.000136	CcSEcCtD
Dasatinib—Headache—Epirubicin—pancreatic cancer	1.59e-05	0.000135	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—pancreatic cancer	1.55e-05	0.000132	CcSEcCtD
Dasatinib—Nausea—Epirubicin—pancreatic cancer	1.51e-05	0.000128	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—pancreatic cancer	1.49e-05	0.000127	CcSEcCtD
Dasatinib—Rash—Doxorubicin—pancreatic cancer	1.48e-05	0.000126	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—pancreatic cancer	1.48e-05	0.000126	CcSEcCtD
Dasatinib—Headache—Doxorubicin—pancreatic cancer	1.47e-05	0.000125	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—pancreatic cancer	1.39e-05	0.000119	CcSEcCtD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	7.52e-07	5.93e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—pancreatic cancer	7.52e-07	5.93e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—pancreatic cancer	7.51e-07	5.92e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.49e-07	5.91e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	7.46e-07	5.88e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	7.44e-07	5.87e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—pancreatic cancer	7.44e-07	5.86e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—pancreatic cancer	7.43e-07	5.86e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—pancreatic cancer	7.43e-07	5.86e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—pancreatic cancer	7.43e-07	5.86e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—pancreatic cancer	7.4e-07	5.84e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—pancreatic cancer	7.4e-07	5.83e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—pancreatic cancer	7.4e-07	5.83e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—pancreatic cancer	7.39e-07	5.82e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—pancreatic cancer	7.37e-07	5.81e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—pancreatic cancer	7.36e-07	5.8e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—pancreatic cancer	7.35e-07	5.8e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—pancreatic cancer	7.34e-07	5.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—pancreatic cancer	7.33e-07	5.78e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—pancreatic cancer	7.33e-07	5.78e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—pancreatic cancer	7.32e-07	5.77e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	7.31e-07	5.76e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—pancreatic cancer	7.3e-07	5.76e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	7.3e-07	5.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—pancreatic cancer	7.29e-07	5.75e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—pancreatic cancer	7.25e-07	5.72e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—pancreatic cancer	7.25e-07	5.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—pancreatic cancer	7.23e-07	5.7e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—STK11—pancreatic cancer	7.22e-07	5.69e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—pancreatic cancer	7.17e-07	5.65e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—pancreatic cancer	7.17e-07	5.65e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—pancreatic cancer	7.16e-07	5.64e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—pancreatic cancer	7.16e-07	5.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	7.15e-07	5.63e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—pancreatic cancer	7.14e-07	5.63e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—pancreatic cancer	7.14e-07	5.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CD—pancreatic cancer	7.09e-07	5.59e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—pancreatic cancer	7.07e-07	5.57e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—pancreatic cancer	7.04e-07	5.55e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—pancreatic cancer	7.02e-07	5.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—pancreatic cancer	7.01e-07	5.52e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—pancreatic cancer	7e-07	5.52e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—pancreatic cancer	6.99e-07	5.51e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	6.98e-07	5.5e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—pancreatic cancer	6.98e-07	5.5e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	6.97e-07	5.5e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—pancreatic cancer	6.96e-07	5.49e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—pancreatic cancer	6.95e-07	5.48e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—pancreatic cancer	6.94e-07	5.47e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	6.93e-07	5.47e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—pancreatic cancer	6.93e-07	5.46e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	6.92e-07	5.45e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—pancreatic cancer	6.9e-07	5.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—pancreatic cancer	6.89e-07	5.43e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—pancreatic cancer	6.87e-07	5.41e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—pancreatic cancer	6.83e-07	5.38e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—pancreatic cancer	6.82e-07	5.38e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—pancreatic cancer	6.8e-07	5.36e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	6.79e-07	5.35e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	6.78e-07	5.35e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.77e-07	5.34e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—pancreatic cancer	6.77e-07	5.34e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—pancreatic cancer	6.75e-07	5.32e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—pancreatic cancer	6.74e-07	5.31e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	6.72e-07	5.3e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	6.72e-07	5.3e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—pancreatic cancer	6.72e-07	5.3e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—pancreatic cancer	6.72e-07	5.3e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—pancreatic cancer	6.71e-07	5.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	6.71e-07	5.29e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	6.71e-07	5.29e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—pancreatic cancer	6.7e-07	5.28e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	6.65e-07	5.24e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—pancreatic cancer	6.65e-07	5.24e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—pancreatic cancer	6.62e-07	5.22e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—pancreatic cancer	6.58e-07	5.19e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—pancreatic cancer	6.58e-07	5.19e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—pancreatic cancer	6.57e-07	5.18e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—pancreatic cancer	6.56e-07	5.17e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—pancreatic cancer	6.55e-07	5.16e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—pancreatic cancer	6.53e-07	5.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—pancreatic cancer	6.48e-07	5.11e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—pancreatic cancer	6.48e-07	5.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—pancreatic cancer	6.47e-07	5.1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—pancreatic cancer	6.46e-07	5.1e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—pancreatic cancer	6.46e-07	5.09e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—pancreatic cancer	6.44e-07	5.08e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	6.42e-07	5.06e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—pancreatic cancer	6.42e-07	5.06e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	6.41e-07	5.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—pancreatic cancer	6.39e-07	5.04e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—pancreatic cancer	6.34e-07	5e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—pancreatic cancer	6.34e-07	5e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—pancreatic cancer	6.32e-07	4.99e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—pancreatic cancer	6.32e-07	4.99e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—pancreatic cancer	6.3e-07	4.97e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	6.28e-07	4.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	6.25e-07	4.93e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	6.25e-07	4.93e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—pancreatic cancer	6.24e-07	4.92e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	6.23e-07	4.91e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—pancreatic cancer	6.23e-07	4.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—pancreatic cancer	6.22e-07	4.91e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—pancreatic cancer	6.22e-07	4.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	6.22e-07	4.9e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.21e-07	4.89e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—pancreatic cancer	6.2e-07	4.89e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	6.19e-07	4.88e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—pancreatic cancer	6.19e-07	4.88e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—pancreatic cancer	6.18e-07	4.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—pancreatic cancer	6.18e-07	4.87e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD44—pancreatic cancer	6.18e-07	4.87e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—pancreatic cancer	6.16e-07	4.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—pancreatic cancer	6.15e-07	4.85e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—pancreatic cancer	6.14e-07	4.84e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—pancreatic cancer	6.12e-07	4.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	6.11e-07	4.82e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—pancreatic cancer	6.1e-07	4.81e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—pancreatic cancer	6.09e-07	4.8e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—pancreatic cancer	6.08e-07	4.79e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	6.07e-07	4.78e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	6.03e-07	4.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—pancreatic cancer	6.02e-07	4.75e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—pancreatic cancer	6.02e-07	4.74e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—pancreatic cancer	6.01e-07	4.74e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—pancreatic cancer	5.98e-07	4.72e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—pancreatic cancer	5.96e-07	4.7e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—pancreatic cancer	5.94e-07	4.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GCG—pancreatic cancer	5.92e-07	4.67e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—pancreatic cancer	5.89e-07	4.64e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	5.89e-07	4.64e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—pancreatic cancer	5.86e-07	4.62e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—pancreatic cancer	5.83e-07	4.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—pancreatic cancer	5.8e-07	4.57e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	5.8e-07	4.57e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—pancreatic cancer	5.78e-07	4.56e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	5.77e-07	4.55e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—pancreatic cancer	5.75e-07	4.54e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	5.74e-07	4.53e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—pancreatic cancer	5.72e-07	4.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—pancreatic cancer	5.71e-07	4.5e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.71e-07	4.5e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	5.69e-07	4.49e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—pancreatic cancer	5.69e-07	4.49e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—pancreatic cancer	5.68e-07	4.48e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—pancreatic cancer	5.67e-07	4.47e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—pancreatic cancer	5.67e-07	4.47e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—pancreatic cancer	5.65e-07	4.46e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—pancreatic cancer	5.62e-07	4.43e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—pancreatic cancer	5.6e-07	4.41e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—pancreatic cancer	5.59e-07	4.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STK11—pancreatic cancer	5.57e-07	4.39e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—pancreatic cancer	5.56e-07	4.39e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—pancreatic cancer	5.53e-07	4.36e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—pancreatic cancer	5.51e-07	4.34e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—pancreatic cancer	5.48e-07	4.32e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	5.48e-07	4.32e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	5.45e-07	4.3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	5.45e-07	4.29e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—pancreatic cancer	5.43e-07	4.28e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—pancreatic cancer	5.42e-07	4.27e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	5.4e-07	4.25e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—pancreatic cancer	5.39e-07	4.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	5.38e-07	4.24e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—pancreatic cancer	5.38e-07	4.24e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—pancreatic cancer	5.38e-07	4.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—pancreatic cancer	5.37e-07	4.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—pancreatic cancer	5.36e-07	4.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—pancreatic cancer	5.34e-07	4.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	5.3e-07	4.18e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—pancreatic cancer	5.29e-07	4.17e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—pancreatic cancer	5.19e-07	4.09e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	5.13e-07	4.05e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—pancreatic cancer	5.11e-07	4.03e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—pancreatic cancer	5.08e-07	4.01e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—pancreatic cancer	5.05e-07	3.98e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—pancreatic cancer	5.02e-07	3.96e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.02e-07	3.96e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—pancreatic cancer	5.01e-07	3.95e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	5.01e-07	3.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	5e-07	3.94e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—pancreatic cancer	4.98e-07	3.92e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—pancreatic cancer	4.97e-07	3.91e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—pancreatic cancer	4.95e-07	3.9e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	4.93e-07	3.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—pancreatic cancer	4.92e-07	3.88e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	4.91e-07	3.87e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	4.9e-07	3.87e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—pancreatic cancer	4.86e-07	3.83e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—pancreatic cancer	4.82e-07	3.8e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	4.81e-07	3.79e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—pancreatic cancer	4.8e-07	3.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.79e-07	3.78e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.78e-07	3.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—pancreatic cancer	4.78e-07	3.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—pancreatic cancer	4.76e-07	3.76e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—pancreatic cancer	4.76e-07	3.75e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—pancreatic cancer	4.76e-07	3.75e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—pancreatic cancer	4.73e-07	3.73e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—pancreatic cancer	4.73e-07	3.73e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—pancreatic cancer	4.7e-07	3.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	4.63e-07	3.65e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.56e-07	3.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—pancreatic cancer	4.55e-07	3.59e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—pancreatic cancer	4.5e-07	3.54e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—pancreatic cancer	4.44e-07	3.5e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—pancreatic cancer	4.43e-07	3.49e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—pancreatic cancer	4.43e-07	3.49e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.4e-07	3.47e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—pancreatic cancer	4.4e-07	3.47e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.37e-07	3.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—pancreatic cancer	4.34e-07	3.42e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.33e-07	3.42e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	4.33e-07	3.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	4.26e-07	3.36e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—pancreatic cancer	4.24e-07	3.34e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—pancreatic cancer	4.18e-07	3.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—pancreatic cancer	4.12e-07	3.25e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—pancreatic cancer	4.1e-07	3.23e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—pancreatic cancer	4.03e-07	3.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—pancreatic cancer	4.02e-07	3.17e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.01e-07	3.16e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—pancreatic cancer	3.97e-07	3.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	3.94e-07	3.1e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—pancreatic cancer	3.9e-07	3.07e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—pancreatic cancer	3.78e-07	2.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—pancreatic cancer	3.77e-07	2.97e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—pancreatic cancer	3.65e-07	2.87e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.53e-07	2.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.52e-07	2.77e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.49e-07	2.75e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—pancreatic cancer	3.49e-07	2.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	3.48e-07	2.74e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.46e-07	2.73e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.39e-07	2.68e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	3.34e-07	2.63e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.09e-07	2.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—pancreatic cancer	3.08e-07	2.43e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.02e-07	2.38e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.89e-07	2.28e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.73e-07	2.15e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.69e-07	2.12e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.67e-07	2.1e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.67e-07	2.1e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.33e-07	1.84e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—pancreatic cancer	2.18e-07	1.72e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.13e-07	1.68e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.74e-07	1.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.64e-07	1.29e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.34e-07	1.06e-06	CbGpPWpGaD
